KEGG   DRUG: Tezepelumab
Entry
D11771                      Drug                                   
Name
Tezepelumab (USAN/INN);
Tezepelumab (genetical recombination) (JAN);
Tezepelumab-ekko;
Tezspire (TN)
Product
Formula
C6400H9844N1732O1992S52
Exact mass
144498.7714
Mol weight
144588.53
Sequence
(Heavy chain)
QMQLVESGGG VVQPGRSLRL SCAASGFTFR TYGMHWVRQA PGKGLEWVAV IWYDGSNKHY
ADSVKGRFTI TRDNSKNTLN LQMNSLRAED TAVYYCARAP QWELVHEAFD IWGQGTMVTV
SSASTKGPSV FPLAPCSRST SESTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSNFGT QTYTCNVDHK PSNTKVDKTV ERKCCVECPP CPAPPVAGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVQFNWYV DGVEVHNAKT KPREEQFNST
FRVVSVLTVV HQDWLNGKEY KCKVSNKGLP APIEKTISKT KGQPREPQVY TLPPSREEMT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPMLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPGK
(Light chain)
SYVLTQPPSV SVAPGQTARI TCGGNNLGSK SVHWYQQKPG QAPVLVVYDD SDRPSWIPER
FSGSNSGNTA TLTISRGEAG DEADYYCQVW DSSSDHVVFG GGTKLTVLGQ PKAAPSVTLF
PPSSEELQAN KATLVCLISD FYPGAVTVAW KADSSPVKAG VETTTPSKQS NNKYAASSYL
SLTPEQWKSH RSYSCQVTHE GSTVEKTVAP TECS
(Disulfide bridge: H22-H96, H136-L213, H149-H205, H224-H'224, H225-H'225, H228-H'228, H231-H'231, H262-H322, H368-H426, H'22-H'96, H'136-L'213, H'149-H'205, H'262-H'322, H'368-H'426, L22-L87, L136-L195, L'22-L'87, L'136-L'195)
  Type
Peptide
Remark
Therapeutic category: 2290
ATC code: R03DX11
Product: D11771<JP/US>
Efficacy
Anti-inflammatory, Anti thymic stromal lymphopoietin antibody
  Disease
Asthma [DS:H00079]
  Type
Monoclonal antibody
Comment
Treatment of asthma and atopic dermatitis
Target
TSLP [HSA:85480] [KO:K05436]
  Pathway
hsa04060  Cytokine-cytokine receptor interaction
hsa04630  JAK-STAT signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
    R03DX Other systemic drugs for obstructive airway diseases
     R03DX11 Tezepelumab
      D11771  Tezepelumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Respiratory Tract Agents, Other
   Immunomodulators
    Tezepelumab
     D11771  Tezepelumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D11771  Tezepelumab (USAN/INN); Tezepelumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   CSF and other factors
    TSLP
     D11771  Tezepelumab (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11771
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11771
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11771
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11771
Other DBs
CAS: 1572943-04-4
PubChem: 405226637
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system